Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved ...

Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...

Stocks rose sharply Monday after the U.S. and China said Monday they had reached an agreement over the weekend to temporarily ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...

Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of the 15 Best High-Yield Dividend Stocks for 2025 and Beyond. In this article, we are going to ...

Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these ...